title: Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
authors.forename: Judith
authors.initials: J
authors.lastname: Korner
authors.forename: Janet
authors.initials: J
authors.lastname: Lo
authors.forename: Pamela U
authors.initials: PU
authors.lastname: Freda
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Wardlaw
mesh_terms: D019440:Anti-Obesity Agents; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D004873:Ergolines; D000077465:Cabergoline